Peripheral Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Transplantation of circulating progenitor/stem cells collected before and stored during administration of marrow-ablative antitumor therapy has restored sustained hematopoiesis for patients with a variety of malignancies. One of the most common diseases so treated is refractory or relapsed non-Hodgkin's lymphoma (NHL). Autologous peripheral stem cell transplantation (PSCT) often has been used rather than autologous bone marrow transplantation (ABMT) because NHL commonly involves the bone marrow, and because, in some situations, PSCT provides earlier engraftment than ABMT. Between July 1986 and September 1992, 170 adult patients with refractory or relapsed NHL were treated with high-dose therapy and PSCT at the University of Nebraska Medical Center (UNMC). With a median follow-up of 469 days for the evaluable survivors, the actuarial progression-free survival for 167 patients at 6 years after PSCT was 30%. High-dose therapy and PSCT for NHL patients has resulted in long-term progression-free survival and probably cure for some patients. The role of PSCT in this disease continues to evolve.

Original languageEnglish (US)
Pages (from-to)361-362
Number of pages2
JournalJournal of hematotherapy
Volume2
Issue number3
DOIs
StatePublished - Jan 1 1993

Fingerprint

Peripheral Blood Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Autologous Transplantation
Bone Marrow Transplantation
Disease-Free Survival
Stem Cells
Bone Marrow
Hematopoiesis
Survivors
Therapeutics
Transplantation
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Peripheral Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients. / Kessinger, A.; Vose, Julie Marie; Bierman, Philip Jay; Bishop, M.; Armitage, James Olen.

In: Journal of hematotherapy, Vol. 2, No. 3, 01.01.1993, p. 361-362.

Research output: Contribution to journalArticle

@article{b5e1ee206dee4ca59fd080c8ab16e0dc,
title = "Peripheral Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients",
abstract = "Transplantation of circulating progenitor/stem cells collected before and stored during administration of marrow-ablative antitumor therapy has restored sustained hematopoiesis for patients with a variety of malignancies. One of the most common diseases so treated is refractory or relapsed non-Hodgkin's lymphoma (NHL). Autologous peripheral stem cell transplantation (PSCT) often has been used rather than autologous bone marrow transplantation (ABMT) because NHL commonly involves the bone marrow, and because, in some situations, PSCT provides earlier engraftment than ABMT. Between July 1986 and September 1992, 170 adult patients with refractory or relapsed NHL were treated with high-dose therapy and PSCT at the University of Nebraska Medical Center (UNMC). With a median follow-up of 469 days for the evaluable survivors, the actuarial progression-free survival for 167 patients at 6 years after PSCT was 30{\%}. High-dose therapy and PSCT for NHL patients has resulted in long-term progression-free survival and probably cure for some patients. The role of PSCT in this disease continues to evolve.",
author = "A. Kessinger and Vose, {Julie Marie} and Bierman, {Philip Jay} and M. Bishop and Armitage, {James Olen}",
year = "1993",
month = "1",
day = "1",
doi = "10.1089/scd.1.1993.2.361",
language = "English (US)",
volume = "2",
pages = "361--362",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Peripheral Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients

AU - Kessinger, A.

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Bishop, M.

AU - Armitage, James Olen

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Transplantation of circulating progenitor/stem cells collected before and stored during administration of marrow-ablative antitumor therapy has restored sustained hematopoiesis for patients with a variety of malignancies. One of the most common diseases so treated is refractory or relapsed non-Hodgkin's lymphoma (NHL). Autologous peripheral stem cell transplantation (PSCT) often has been used rather than autologous bone marrow transplantation (ABMT) because NHL commonly involves the bone marrow, and because, in some situations, PSCT provides earlier engraftment than ABMT. Between July 1986 and September 1992, 170 adult patients with refractory or relapsed NHL were treated with high-dose therapy and PSCT at the University of Nebraska Medical Center (UNMC). With a median follow-up of 469 days for the evaluable survivors, the actuarial progression-free survival for 167 patients at 6 years after PSCT was 30%. High-dose therapy and PSCT for NHL patients has resulted in long-term progression-free survival and probably cure for some patients. The role of PSCT in this disease continues to evolve.

AB - Transplantation of circulating progenitor/stem cells collected before and stored during administration of marrow-ablative antitumor therapy has restored sustained hematopoiesis for patients with a variety of malignancies. One of the most common diseases so treated is refractory or relapsed non-Hodgkin's lymphoma (NHL). Autologous peripheral stem cell transplantation (PSCT) often has been used rather than autologous bone marrow transplantation (ABMT) because NHL commonly involves the bone marrow, and because, in some situations, PSCT provides earlier engraftment than ABMT. Between July 1986 and September 1992, 170 adult patients with refractory or relapsed NHL were treated with high-dose therapy and PSCT at the University of Nebraska Medical Center (UNMC). With a median follow-up of 469 days for the evaluable survivors, the actuarial progression-free survival for 167 patients at 6 years after PSCT was 30%. High-dose therapy and PSCT for NHL patients has resulted in long-term progression-free survival and probably cure for some patients. The role of PSCT in this disease continues to evolve.

UR - http://www.scopus.com/inward/record.url?scp=0027853937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027853937&partnerID=8YFLogxK

U2 - 10.1089/scd.1.1993.2.361

DO - 10.1089/scd.1.1993.2.361

M3 - Article

VL - 2

SP - 361

EP - 362

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 3

ER -